Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eisai Ltd ADR (OP:ESALY)

N/A UNCHANGED
Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eisai Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
News headline image
The Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck's Keytruda Evaluated In Combination With Microbiome Therapeutic In... 
Via Benzinga
News headline image
The Ruble Is Rubble ↗
MSCI says Russian companies are 
Via Talk Markets
News headline image
Merck-Eisai's Keytruda/Lenvima Combo Scores Japanese Approval For Kidney Cancer Setting ↗
The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Merck & Co Inc's (NYSE: MRK) Keytruda/Lenvima combo therapy for radically... 
Via Benzinga
News headline image
Dampening Exuberance ↗
The bond sell-off halted today but the Fed's plans mean this will resume. 
Via Talk Markets
News headline image
Weakened Tech Stocks ↗
There was a 0.5% rise in UK interest rates, twice what had been anticipated and moreover early, because of inflation risks. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In... 
Via Benzinga
News headline image
CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply ↗
The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild... 
Via Benzinga
News headline image
Christmas is Coming ↗
November saw a very modest increase in consumer spending, 0.6%. That means we are probably making up for it this month. 
Via Talk Markets
News headline image
A Bit Of Good News ↗
US growth figures for Q3 were up from forecasts of 2.1% at 2.3% but well down from the prior quarter level of 6.7%. 
Via Talk Markets
News headline image
Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026 ↗
Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) are looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer’s... 
Via Benzinga
News headline image
Uncertain Times ↗
The UK inflation rate last month was 5.1%, not a good omen. 
Via Talk Markets
News headline image
Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma ↗
The European Commission has approved a combination of Merck & Co Inc's (NYSE: MRK) Keytruda plus Eisai Co Ltd's (OTC: ESALY) Lenvima for... 
Via Benzinga
News headline image
Why Are Biogen Shares Gaining Today? ↗
​​​​​​Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease. Related:... 
Via Benzinga
News headline image
Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial ↗
Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) announced results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &... 
Via Benzinga
News headline image
Chinese Growth Level ↗
The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues. 
Via Talk Markets
News headline image
Europe's Unicorns ↗
After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit. 
Via Talk Markets
News headline image
Multiple Bits Of Bad News ↗
Republican debt ceiling brinkmanship boosted yields way over what stocks can pay, with info-tech the big loser. 
Via Talk Markets
News headline image
Eisai, Biogen Initiate Rolling Submission For New Alzheimer's Drug ↗
Eisai Co Ltd (OTC: ESALY) began its application process for lecanemab (BAN2401) for early Alzheimer's disease using an accelerated approval pathway. Lecanemab... 
Via Benzinga
News headline image
A Day Of Huge Market Moves ↗
It was a day of huge market moves and several reporting companies. Trudeau won but did not get a parliamentary majority. 
Via Talk Markets
News headline image
Pressure Day ↗
Today a recovery came to markets with a particular impact on uranium shares. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
News headline image
A Weak Week ↗
Chinese car-maker Nio appears to have been able to weather the Beijing crackdown on foreign listed firms better than later entrants. 
Via Talk Markets
News headline image
Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential ↗
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) 
Via Benzinga
News headline image
Dr Reddy's To Sell Its Anti-Cancer Agent To Citius Pharma ↗
Citius Pharmaceuticals Inc has agreed to acquire anti-cancer agent E7777 from Dr. Reddy's Laboratories Ltd (NYSE: RDY). E7777 is an engineered IL-2-... 
Via Benzinga
News headline image
Mu - The Newest Worry ↗
Today London and New York fell on the huge drop in new employment levels in August. 
Via Talk Markets
News headline image
Amid Medicare Uncertainty, Biogen Offers Its Alzheimer's Drug For Free ↗
Biogen Inc (NASDAQ: BIIB) is providing its controversial and expensive new Alzheimer's drug, free of charge for some patients amid slow claim reviews by Medicare, ... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In A Light Week ↗
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. and BioNTech SE. The stocks subsequently moved back and... 
Via Talk Markets
News headline image
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week ↗
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. (NYSE: PFE) and BioNTech SE (... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.